The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Efficacy of odronextamab in R/R DLBCL & determining the optimal sequencing of immune therapies
Michelle Poon, MD, National University of Singapore, Singapore, shares some insights into the efficacy of odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), based on findings from the ELM-2 trial (NCT03888105). Dr Poon then goes on to discuss the importance of determining the optimal sequencing of bispecifics and CAR-T cells in this disease. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
